
Last updated: 2026-09-28 21:12:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
United Therapeutics Corp. (UTHR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $485.85, with a market capitalization of $20.39B and a P/E ratio of 15.56. Over the past 52 weeks, its price has ranged from $409.07 to $609.35. This page covers its latest market performance, valuation, price trends and company information.
$20.39B | |
$473.84 | |
$609.35 | |
$9.11 | |
$475.45 | |
517.73K | |
551.25K | |
15.56 | |
$609.35 | |
$409.07 | |
-- | |
-- |
United Therapeutics Corp. (UTHR) is trading at $482.47 in after-hours trading as of 2026-09-28 20:20:00, up 1.48% ($7.01) from the regular-session close of $475.45.
After-hours trading shows how investors are pricing UTHR after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, United Therapeutics Corp. (UTHR) moved from $497.27 to $485.85, representing a decline of 2.30% ($11.42).
The stock traded between $468.97 and $503.33 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 888.43 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 38.3%
UTHR is currently trading at $485.85, placing it 38.3% of the way from its 52-week low of $409.07 to its 52-week high of $609.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1400 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of United Therapeutics Corp. (UTHR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.